|Bid||0.6920 x 1000|
|Ask||0.6974 x 800|
|Day's Range||0.6800 - 0.7100|
|52 Week Range||0.2600 - 1.3100|
|Beta (5Y Monthly)||4.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2020 - Aug 21, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IGC filed a patent application with the USPTO for a new cannabinoid formulation intended for treatment of pain in humans and veterinary animals.
IGC received Notice of Allowance from United States Patent & Trademark Office for its cannabinoid formulation to treat seizures in humans & animals.
IGC announces its financial results for the Fiscal Year Ended March 31, 2020.